Overall, our findings emphasize the importance of CD166 expression as a possible diagnostic marker in the context of BI-RADS assessment, adding to our expanding awareness of its potential utility in the early diagnosis and monitoring of breast cancer. Here, ALCAM is linked to breast carcinoma.